Bafna Pharmaceuticals Ltd - 532989 - Clarification sought from Bafna Pharmaceuticals Ltd
The Exchange has sought clarification from Bafna Pharmaceuticals Ltd on March 18, 2021 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited. BAFNA PHARMACEUTICALS LTD. - 532989 - Outcome Of The Board Meeting Held On 12Th February 2021
We would like to inform you that the Board at its meeting held on today approved: 1. The un-audited financial results for the Third Quarter ending 31st December 2020. Please find attached the un-audited financial results for Third Quarter ending 31st December 2020 along with the Limited Review Report obtained from the statutory auditor of the Company BAFNA PHARMACEUTICALS LTD. - 532989 - Outcome Of Board Meeting
We would like to inform you that the Board at its meeting held on today approved: 1. The un-audited financial results for the Third Quarter ending 31st December 2020. Please find attached the un-audited financial results for Third Quarter ending 31st December 2020 along with the Limited Review Report obtained from the statutory auditor of the Company. BAFNA PHARMACEUTICALS LTD. - 532989 - Board Meeting Intimation for To Inter Alia Consider And Adopt Un-Audited Financial Results For The Quarter And Nine Months Ended 31St December 2020 And Any Other Business With The Permission Of The Chair.
BAFNA PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2021 ,inter alia, to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Friday, 12th February 2021, to inter alia consider and adopt un-audited financial results for the quarter and nine months ended 31st December 2020 and any other business with the permission of the Chair. BAFNA PHARMACEUTICALS LTD. - 532989 - Sub.:- Disclosure Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Details Of Related Party Transactions
In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, We hereby submit related party transactions as at 30th September 2020. BAFNA PHARMACEUTICALS LTD. - 532989 - Shareholding for the Period Ended December 31, 2020
Bafna Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here BAFNA PHARMACEUTICALS LTD. - 532989 - Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- JITENDRA KUMAR PALDesignation :- Company Secretary and Compliance Officer BAFNA PHARMACEUTICALS LTD. - 532989 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SRJR Lifesciences LLP BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Resignation of Director
Resignation of Mr. Battu Harish Laxmaiah (06390117) as Director of the Company with effect from 12th November 2020. BAFNA PHARMACEUTICALS LTD. - 532989 - Announcement under Regulation 30 (LODR)-Change in Directorate
1.Appointment of Ms. Ravichandran Chitra (DIN:07749125) as an Independent Director (Additional Director Non Executive) with effect from 12th November 2020. Details as per (Annexure-1) 2. Appointment of Mr. Atul Sachdeva (DIN: 07645130) as an Additional Director (Non-executive & Non- Independent) with effect from 12th November 2020. Details as per (Annexure-2) Resignation of Mr. Battu Harish Laxmaiah (06390117) as Director of the Company with effect from 12th November 2020.